Navigation Links
PI-88 Data to be Presented at Key International Conferences

BRISBANE, Australia, March 12, 2007: Progen Industries Limited (ASX: PGL; NASDAQ: PGLA) is pleased to announce that its PI-88 Phase II liver cancer data has been accepted for late breaking news presentation by the European Association for the Study of the Liver (EASL). Progen will also be presenting the results of this liver cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2007.


In expectation of having final data fully analysed and ready for disclosure, Progen is planning for Professor PJ Chen, Principal Investigator of this trial, to present the 48 week data for all 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in Barcelona, Spain from April 11-15, 2007.


Dr. Anand Gautam, Progen's VP of Discovery Research, will be presenting results at the AACR Annual Meeting 2007, which will be held in Los Angeles, U.S, from April 14-18, 2007.


About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.


Progen's three key areas of focus are:

* Clinical Development - via a focused clinical trial program involving its two compounds PI-88 and PI-166.

* Drug Discovery - projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes.

* Manufacturing Services - PI-88 manufacturing development and supply for the clinical program and contract manufacturing services.


Keywords - Progen, liver cancer, PI-88.

Web links to selected recent news and other information about Progen:


Half yearly report/half year accounts www.progen.com.au/?page=nepress2007.html

SPP exceeds expectations www.progen.com.au/?page=nepress2007.html

Progen - Notice of General Meeting www.progen.com.au/?page=nepress2007.html

Progen buys back royalty from Medigen www.progen.com.au/?page=nepress2007.html

Capital Raising to Progress PI-88 to Phase 3 www.progen.com.au/?page=nepress2006.html

Preliminary Results for Phase 2 liver cancer trial www.progen.com.au/?page=nepress2006.html

PI-88 mode of action www.progen.com.au/?page=repi-88.html

Progen's drug development pipeline www.progen.com.au/?page=pihome.html

Progen Industries Ltd www.progen.com.au <http://www.progen.com.au/>


Media and Investor Relations:


Rebecca Piercy

Buchan Consulting

(02) 9237 2800 /

0422 916 422

rpiercy@bcg.com.au rwilson@bcg.com.au>


Progen Information:


Justus Homburg

Chief Executive Officer

Progen Industries Limited

justus.homburg@progen.com.au

Ph: 61 7 3842 3333


Linton Burns

Chief Financial Officer

Progen Industries

linton.burns@progen.com.au

Ph: 61 7 3842 3333

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capitals needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Stock Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.


'"/>




Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...  Oxis International Inc. (OTC/QB: OXIS) announced today that ... a "clinical trial triumph" after one of the first ... remission. Daniel Vallera , a research ... --> Daniel Vallera , a research ... --> An article on the University ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... AKIVA, Israel , February 10, 2016 ... a leader in the field of cartilage repair, announces ... February 5, 2016. The $15 million investment was led ... Chinese pharmaceutical manufacturer, and was joined by existing Regentis ... Holdings and both the Technion Research & Development Foundation ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through ... Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. ... the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company ...
(Date:2/11/2016)... Diego, CA (PRWEB) , ... February 11, 2016 , ... ... which was held in San Diego, CA, on February 6th & 7th, 2016 according ... combine for those who were not invited to the NFL’s combine in Indianapolis,” says ...
(Date:2/11/2016)... ... 11, 2016 , ... The book, “Computers Should Just Work!”, provides a basic, ... your IT consultant before signing a contract and how to spot an incompetent or ... relying heavily on e-mail and technology, it’s more important than ever to make sure ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... Culver City, California (PRWEB) , ... February 10, ... ... Molecular Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will ... The theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will ...
Breaking Medicine News(10 mins):